Goldman Sachs Downgrades Johnson & Johnson (JNJ) to Sell, Sees Limited Upside

Article Related Articles (1) Stock Quotes (2) Comments (0)

Goldman Sachs downgraded Johnson & Johnson (NYSE: JNJ) from Neutral to Sell with a price target of $72.00, saying they see limited upside.

The firm said they only see 7% upside for JNJ, versus 14% average upside for the rest of the group.

"Although JNJ has potential for improved growth, we believe this is already captured
in valuation," the analyst said. "We see JNJ as lacking transformational pipeline opportunities and less inclined to do shareholder-friendly capital allocation."

Goldman upgraded Eli Lilly (NYSE: LLY) from Sell to Neutral, as noted earlier.

For an analyst ratings summary and ratings history on Johnson & Johnson click here. For more ratings news on Johnson & Johnson click here.

Shares of Johnson & Johnson closed at $69.44 yesterday, with a 52 week range of $61.05-$69.75.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Goldman Sachs Downgrades Deere (DE) to Sell, Sees 5% Downside
• SunTrust Robinson Humphrey Downgrades Stryker (SYK) to Reduce
• Deutsche Bank Downgrades TRW Automotive Holdings (TRW) to Hold

Create E-mail Alert Related Categories

Downgrades, Hot Downgrades

Related Entities

Goldman Sachs

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?